JP2020515581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515581A5 JP2020515581A5 JP2019553220A JP2019553220A JP2020515581A5 JP 2020515581 A5 JP2020515581 A5 JP 2020515581A5 JP 2019553220 A JP2019553220 A JP 2019553220A JP 2019553220 A JP2019553220 A JP 2019553220A JP 2020515581 A5 JP2020515581 A5 JP 2020515581A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- population
- genetically engineered
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023011257A JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479930P | 2017-03-31 | 2017-03-31 | |
| US62/479,930 | 2017-03-31 | ||
| PCT/US2018/025394 WO2018183842A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023011257A Division JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515581A JP2020515581A (ja) | 2020-05-28 |
| JP2020515581A5 true JP2020515581A5 (enExample) | 2021-05-06 |
| JP7278961B2 JP7278961B2 (ja) | 2023-05-22 |
Family
ID=63677091
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11938153B2 (enExample) |
| EP (2) | EP3600357A4 (enExample) |
| JP (6) | JP7278961B2 (enExample) |
| CN (3) | CN110603044B (enExample) |
| AU (3) | AU2018243571B2 (enExample) |
| CA (2) | CA3057372A1 (enExample) |
| WO (2) | WO2018183888A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019110815A1 (en) * | 2017-12-07 | 2019-06-13 | Julius-Maximilians-Universität Würzburg | Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitors |
| US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
| CN113573719A (zh) * | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| AU2020231810B2 (en) * | 2019-03-01 | 2025-12-18 | National University Of Singapore | Engineered immune cells |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| EP4008347B1 (en) * | 2019-08-01 | 2025-04-30 | Mie University | GD2-BINDING MOLECULE |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| GB202000934D0 (en) * | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| KR20230019460A (ko) * | 2020-05-29 | 2023-02-08 | 상하이 준셀 테라퓨틱스 컴퍼니 리미티드 | 종양 침윤 림프구의 종자세포 배지 및 이의 용도 |
| BR112022025536A2 (pt) * | 2020-06-19 | 2023-01-17 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antígeno de células anti-t para uso em combinação com o inibidor da angiogênese |
| IL300543A (en) * | 2020-09-24 | 2023-04-01 | Hoffmann La Roche | Prevention or reduction of adverse effects associated with a bispecific T-cell antibody |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022094314A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
| WO2022210487A1 (ja) * | 2021-03-29 | 2022-10-06 | タカラバイオ株式会社 | 抗原に特異的な受容体を発現する免疫細胞の製造方法 |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| JP2024514281A (ja) * | 2021-04-23 | 2024-04-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｋ細胞係合剤関連の有害作用の防止または軽減 |
| EP4334443A1 (en) * | 2021-05-07 | 2024-03-13 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Method for constitutive malt1 protease activation |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| CN115677861B (zh) * | 2021-07-29 | 2026-03-06 | 上海科技大学 | 一种泛素偶联修饰的嵌合抗原受体及免疫细胞 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| US20230313138A1 (en) | 2021-10-28 | 2023-10-05 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| IL317580A (en) * | 2022-06-13 | 2025-02-01 | Univ California | Glycan-dependent enhanced chimeric antigen receptor cells |
| GB202218144D0 (en) * | 2022-12-02 | 2023-01-18 | Univ Oxford Innovation Ltd | Product |
| CN116121196B (zh) * | 2022-12-23 | 2025-07-22 | 广州安捷生物医学技术有限公司 | 一种调控car-t细胞的方法与应用 |
| WO2025221871A1 (en) * | 2024-04-16 | 2025-10-23 | The Trustees Of Columbia University In The City Of New York | Expansion, propagation, and modulation of immune cell subsets by peptides |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057294A (en) | 1995-01-16 | 2000-05-02 | Northern Sydney Area Health Service Of Pacific Highway | Peptide |
| US20050070478A1 (en) | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| GB0523954D0 (en) * | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
| US8173792B2 (en) | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| ATE538377T1 (de) | 2007-04-02 | 2012-01-15 | Acoustic Cytometry Systems Inc | Verfahren zur verbesserten analyse von in einem akustischen feld fokussierten zellen und partikeln |
| EP2614143B1 (en) | 2010-09-08 | 2018-11-07 | Baylor College Of Medicine | Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| CA2857687C (en) * | 2011-12-02 | 2019-07-09 | Stillwater Mining Company | Quantitative precious metals recovery in the presence of interfering metals, salts, and ions |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| IL305629A (en) * | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US9636340B2 (en) * | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| US11041021B2 (en) * | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| EP3172231B1 (en) * | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| US11248058B2 (en) * | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| CN107708710A (zh) * | 2015-03-17 | 2018-02-16 | 嵌合体生物工程公司 | Smart CAR装置,DE CAR多肽,Side CAR及其使用 |
| GB201514328D0 (en) * | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US20230071283A1 (en) | 2016-04-15 | 2023-03-09 | Aimee S. Payne | Compositions and methods for selective protein expression |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2019110815A1 (en) * | 2017-12-07 | 2019-06-13 | Julius-Maximilians-Universität Würzburg | Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitors |
| US20210393628A1 (en) | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
-
2018
- 2018-03-30 EP EP18777667.9A patent/EP3600357A4/en active Pending
- 2018-03-30 JP JP2019553220A patent/JP7278961B2/ja active Active
- 2018-03-30 US US16/499,760 patent/US11938153B2/en active Active
- 2018-03-30 EP EP18775932.9A patent/EP3600323A4/en active Pending
- 2018-03-30 CN CN201880029045.8A patent/CN110603044B/zh active Active
- 2018-03-30 WO PCT/US2018/025459 patent/WO2018183888A2/en not_active Ceased
- 2018-03-30 US US16/499,762 patent/US20200101108A1/en active Pending
- 2018-03-30 CA CA3057372A patent/CA3057372A1/en active Pending
- 2018-03-30 CN CN201880028993.XA patent/CN110582280B/zh active Active
- 2018-03-30 AU AU2018243571A patent/AU2018243571B2/en active Active
- 2018-03-30 CN CN202410272411.XA patent/CN118161496A/zh active Pending
- 2018-03-30 AU AU2018243664A patent/AU2018243664B2/en active Active
- 2018-03-30 WO PCT/US2018/025394 patent/WO2018183842A1/en not_active Ceased
- 2018-03-30 CA CA3057505A patent/CA3057505A1/en active Pending
- 2018-03-30 JP JP2019553214A patent/JP7249287B2/ja active Active
-
2022
- 2022-12-02 JP JP2022193805A patent/JP7674328B2/ja active Active
-
2023
- 2023-01-27 JP JP2023011257A patent/JP2023055805A/ja active Pending
-
2024
- 2024-02-21 US US18/583,096 patent/US20240293461A1/en active Pending
- 2024-06-07 AU AU2024203919A patent/AU2024203919A1/en active Pending
- 2024-07-30 JP JP2024123405A patent/JP2024153812A/ja active Pending
- 2024-11-18 JP JP2024200383A patent/JP2025026930A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amber et al. | TNF‐α: a treatment target or cause of sarcoidosis? | |
| Ma et al. | Tumor necrosis factor α blockade exacerbates murine psoriasis‐like disease by enhancing Th17 function and decreasing expansion of Treg cells | |
| Tanaka et al. | The biology and medical implications of interleukin-6 | |
| Liepelt et al. | Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases | |
| Freudenberg et al. | Critical role of TGF-β and IL-2 receptor signaling in Foxp3 induction by an inhibitor of DNA methylation | |
| Yeager et al. | Glucocorticoid regulation of the inflammatory response to injury | |
| Marvin et al. | TGF‐β signaling in liver metastasis | |
| Willebrand et al. | IL-33-induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF | |
| Climent et al. | Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection | |
| JP2019065028A5 (enExample) | ||
| RU2018136877A (ru) | Способы раннего вмешательства для профилактики или улучшения состояния токсичности | |
| Tanasescu et al. | Advances in the treatment of relapsing-remitting multiple sclerosis | |
| Zhang et al. | Matrix metalloproteinase-9 and stromal cell-derived factor-1 act synergistically to support migration of blood-borne monocytes into the injured spinal cord | |
| Zou et al. | Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer | |
| Kang et al. | Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells | |
| JP2023501602A5 (enExample) | ||
| Aram et al. | Granulocyte-macrophage colony-stimulating factor as a therapeutic target in multiple sclerosis | |
| Schiller et al. | Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer | |
| Naessens et al. | CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| JP2023524434A5 (enExample) | ||
| Levi et al. | Continuous stress disrupts immunostimulatory effects of IL-12 | |
| Cocco et al. | Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia | |
| Fazzi et al. | Phase II trial of maintenance treatment with IL2 and zoledronate in multiple myeloma after bone marrow transplantation: biological and clinical results | |
| Winkler et al. | Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’ |